萬方發展(000638.SZ)子公司擬購買福睿君安80%股權
格隆匯9月27日丨萬方發展(000638.SZ)公佈,公司控股子公司吉林萬方百奧生物科技有限公司於2020年9月27日與北京福睿君安科技有限公司簽訂了《合作意向書》,根據意向書約定萬方百奧擬購買福睿君安80%的股權,獲得福睿君安研發的20價肺炎結合疫苗及人神經生長因子相關技術成果,並負責組織實施項目的後期研發、臨牀及產業化。
本次合作意向書的簽署,有利於公司在疫苗及生物製品領域的項目儲備,增強公司的研發能力,不斷豐富研發品種,對公司未來在生物科技領域的發展有着積極的影響,符合全體股東的利益和公司長遠發展戰略。公司預計該項合作短期內不會對公司的財務狀況造成重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.